Vor Biopharma Inc VOR.OQ VOR.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Vor Biopharma Inc is for a loss of 25 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vor Biopharma Inc is $8.00, above its last closing price of $0.66.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.22 | -0.29 | -0.44 | Missed | -54 |
Sep. 30 2024 | -0.41 | -0.40 | -0.40 | Met | 0.5 |
Jun. 30 2024 | -0.42 | -0.42 | -0.41 | Beat | 1.9 |
Mar. 31 2024 | -0.38 | -0.38 | -0.45 | Missed | -18.9 |
Dec. 31 2023 | -0.52 | -0.50 | -0.39 | Beat | 22.5 |
Sep. 30 2023 | -0.47 | -0.47 | -0.49 | Missed | -4.6 |
Jun. 30 2023 | -0.44 | -0.43 | -0.45 | Missed | -4.1 |
Mar. 31 2023 | -0.39 | -0.38 | -0.43 | Missed | -12.2 |
This summary was machine generated May 5 at 11:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)